Suppression of HMGB1 for treatment of sepsis, ischemia, cancer, and autoimmune disorders is currently the focus of multiple clinical trials applying a range of unique HMGB1 antagonists [104], suggesting significant potential for translation to patients with adenoviral keratoconjunctivitis. The gene discussed is HMGB1; the disease is cancer.